Volume 2 Issue 3 | 2025 | View PDF
Paper Id:IJMSM-V2I3P111
doi: 10.71141/30485037/V2I3P111

Burden and Predictors of Comorbidities Among US Adults With Type 2 Diabetes: A Cross-Sectional Analysis of NHANES 2015–2020

Blessing Malcolm Awukam

Citation:
Blessing Malcolm Awukam, "Burden and Predictors of Comorbidities Among US Adults With Type 2 Diabetes: A Cross-Sectional Analysis of NHANES 2015–2020" International Journal of Multidisciplinary on Science and Management, Vol. 2, No. 3, pp. 104-109, 2025.

Abstract:
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic condition in the United States and is frequently accompanied by other long-term health issues that complicate disease management and worsen outcomes. This cross-sectional study analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning 2015 to 2020 to examine the prevalence and patterns of common comorbidities among U.S. adults aged 18 years and older with T2DM. Using self-reported physician diagnoses and standardized health assessments, the analysis focused on key comorbid conditions including hypertension, obesity, chronic kidney disease, and depression. Logistic regression models and weighted prevalence estimates revealed substantial demographic disparities, with multimorbidity more frequently observed among older adults, individuals with lower income, and certain racial and ethnic minority groups. The findings highlight the complexity of managing T2DM in the context of multimorbidity and underscore the importance of adopting integrated, patient-centered care approaches to improve health outcomes in this population.

Keywords: Type 2 diabetes mellitus, multimorbidity, comorbidities, integrated care, health disparities.

References:
1. International Diabetes Federation, “Diabetes facts & figures,” IDF.org. [Online]. Available: https://idf.org/about-diabetes/diabetes-facts-figures
2. Centers for Disease Control and Prevention, “Data & Statistics on Diabetes,” CDC.gov, 2023. [Online]. Available: https://www.cdc.gov/diabetes/php/data-research/index.html
3. Rodolfo J Galindo et al., “Advances in the Management of type 2 Diabetes in Adults,” BMJ Med., vol. 2, no. 1, 2023.
4. Thomas R. Einarson et al., “Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence from Across the World in 2007–2017,” Cardiovasc Diabetol, vol. 17, 2018.
5. S. T. Skou et al., "Multimorbidity," Nature Reviews Disease Primers, vol. 8, no. 1, 2022.
6. G. Beridze, A. Abbadi, and J. Ars, et al., "Patterns of Multimorbidity in Primary Care Electronic Health Records: A Systematic Review," Journal of Multimorbidity and Comorbidity, vol. 14, 2024.
7. G. R. Cătălina et al., "The role of Neuroinflammation in the Comorbidity of Psychiatric Disorders and Internal Diseases," Healthcare (Basel), vol. 13, no. 7, 2025.
8. N. H. Siam, N. N. Snigdha, N. Tabasumma, and I. Parvin, "Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies," Reviews in Cardiovascular Medicine, vol. 25, no. 12, 2024.
9. L. Liu, X. Wang, M. Gui, F. Ju, L. Cao, and B. Bi, "Investigation of Multimorbidity Patterns and Association Rules in Patients with Type 2 Diabetes Mellitus Using Association Rules Mining Algorithm," Scientific Reports, vol. 15, no. 1, 2025.
10. T. T. Makovski et al., "Multimorbidity and Quality of Life: Systematic Literature Review and Meta-Analysis," Ageing Research Reviews, vol. 53, 2019.
11. M. Kurczewska-Michalak et al., "Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions," Frontiers in Pharmacology, vol. 12, 2021.
12. C. Muth et al., "Evidence Supporting the Best Clinical Management of Patients with Multimorbidity and Polypharmacy: A Systematic Guideline Review and Expert Consensus," Journal of Internal Medicine, vol. 285, no. 3, pp. 272–288, 2019.
13. J. H. Park, S. J. Kim, M. Medina, T. Prochnow, K. Min, and J. Chang, "Are Comorbidities Associated with Differences in Healthcare Charges among Lung Cancer Patients in US Hospitals? Focusing on Variances by Patient and Socioeconomic Factors," Chronic Illness, vol. 20, no. 3, pp. 434–444, 2024.
14. A. Chaturvedi et al., "Social Determinants of Health and Disparities in Hypertension and Cardiovascular Diseases," Hypertension, vol. 81, no. 3, pp. 387–399, 2024.
15. Centers for Disease Control and Prevention, Chronic Kidney Disease in the United States, 2023. [Online]. Available: https://www.cdc.gov/kidney-disease/php/data-research/index.html
16. T. Akinyemiju, M. Jha, J. X. Moore, and M. Pisu, "Disparities in the Prevalence of Comorbidities among US Adults by State Medicaid Expansion Status," Preventive Medicine, vol. 88, pp. 196–202, 2016.
17. C. F. Nwakobe, and I. O. Ilouno, "Polycystic Ovary Syndrome and Infertility in Niger State, Nigeria: Challenges, Outcomes, and Early Intervention," Journal of Prevention, Diagnosis and Management of Human Diseases, vol. 4, no. 6, pp. 1–9, 2024.
18. A. Lim et al., "Social Determinants of Health and Emergency Department Visits Among Older Adults with Multimorbidity: Insight From 2010 to 2018 National Health Interview Survey," BMC Public Health, vol. 24, no. 1, 2024.
19. Zulqarnain Javed et al., "Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease," Circulation: Cardiovascular Quality and Outcomes, vol. 15, no. 1, 2022.
20. Carlos A. Yepes-Cortés et al., "Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique," Diabetes Therapy, vol. 16, no. 5, pp. 813–849, 2025.
21. J. H. Bae, "SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application," Diabetes & Metabolism Journal, vol. 49, no. 3, pp. 386–402, 2025.
22. Bartosz Rolek et al., "SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain," Journal of Cardiovascular Development and Disease, vol. 10, no. 8, 2023.